What is Tarsus Pharmaceuticals, Inc.'s remainder of 2026?

Tarsus Pharmaceuticals, Inc. (TARS) reported remainder of 2026 of $721K in Q1 2026.

How has Tarsus Pharmaceuticals, Inc.'s remainder of 2026 changed year-over-year?

Tarsus Pharmaceuticals, Inc.'s remainder of 2026 decreased by 0.0% year-over-year, from $721K to $721K.

Tarsus Pharmaceuticals, Inc. TARS Remainder of 2026

Remainder of 2026 at other companies

Bausch + LombBLCO

——

Other financials

Income statement

See full

Revenue$162.1M+107%

Gross profit$152.7M+109%

Operating income-$6.1M+76.7%

Net income-$7.0M+72.3%

EPS (diluted)-$0.16+75.0%

Balance sheet

See full

Cash & equivalents$104.2M-41.6%

Total debt$88.7M+22.5%

Total equity$349.0M+1.9%

Total assets$581.1M+16.1%

Cash flow

See full

Operating cash flow-$24.7M-19.4%

CapEx$5.8M+886%

Free cash flow-$30.5M-43.4%

Valuation

See full

Market cap$2.85B+41.1%

Enterprise value$2.83B+47.8%

P/S5.3×-3.3×

Profitability

See full

Gross margin42.7%—

Operating margin-9.5%-4.2pp

Net margin-9%-4.0pp

FCF margin-28%-12.6pp

Returns & leverage

See full

Return on equity-14%-5.2pp

Debt / equity0.3×0.0×

Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s remainder of 2026.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s remainder of 2026?: Tarsus Pharmaceuticals, Inc. (TARS) reported remainder of 2026 of $721K in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s remainder of 2026 changed year-over-year?: Tarsus Pharmaceuticals, Inc.'s remainder of 2026 decreased by 0.0% year-over-year, from $721K to $721K.